### **Overview** - **Founded:** 1988 - **Listed:** BSE (524212), NSE (WANBURY) - **Headquarters:** Maharashtra, India - **Employee Strength:** Over 1,200 - **Operational History:** 37+ years in the pharmaceutical sector - **Global Presence:** Operations in over 50 countries Wanbury Ltd. is an integrated Indian pharmaceutical company operating across two core business segments: **Active Pharmaceutical Ingredients (APIs)** and **Branded Formulations**. The company has completed a two-year operational and financial turnaround and is now positioned for sustained growth, backed by strong regulatory approvals, product innovation, and strategic leadership. --- ### **Business Segments** #### **1. Active Pharmaceutical Ingredients (APIs)** - **Revenue (FY25):** Over ₹530 crore - **H1 FY26 Revenue:** ₹282 crore - **Gross Contribution Margin:** >50% - **Sales Mix:** 50–95% of total company revenue (historical trend) - **Export Share:** >80% of API revenue from global markets **Key Products:** - **Core Molecules:** Metformin (antidiabetic), Sertraline (antidepressant), Tramadol (pain management), Paroxetine (antidepressant), Mefenamic acid (anti-inflammatory), Diphenhydramine (antihistamine), Ketamine Hydrochloride. - **Global Market Leadership:** - **Metformin:** ~11% global market share (one of the world’s largest producers) - **Sertraline:** ~30% global market share - **Tramadol:** ~11% global market share - These positions provide significant pricing influence in competitive markets. **Regulatory Approvals & Manufacturing:** - Owns **two USFDA- and EU-GMP-approved** manufacturing facilities: - **Patalganga, Maharashtra (Multi-purpose Plant):** 400 KL reactor capacity, contributes ~70% of API revenue, employs 450+ people. - **Tanuku, Andhra Pradesh (Dedicated Metformin Plant):** 96 KL capacity, contributes ~30% of API revenue, fully operational. - **Total Installed Reactor Capacity:** 500 KL (expandable to **600 KL** via brownfield expansion) - **Land Bank:** 18 acres (Patalganga) + 2.3 acres (Tanuku) **Growth & Pipeline Strategy:** - **Near-Term Launch (Q4 FY26):** Anesthetic API - **Long-Term Plan:** Launch **4 new API molecules annually starting FY27** - **Pipeline Includes:** Ketamine, Rivaroxaban, Montelukast, Sitagliptin, and others - **Target Markets:** Regulated markets – **US, EU, Brazil** - **Product Selection Framework:** - Focus on mid-sized, high-value, or large-volume molecules - Aim for double-digit market share and ~50% gross margins - Strategic alignment with key client demand and patented molecule supply chains (beyond FY29–30) **Commercial Capabilities:** - Secured **CEP (Certificate of Suitability)** for Dextromethorphan API from EDQM (European Directorate for Quality of Medicines), enabling European market access. - Maintains long-term contracts with leading global generic pharmaceutical players. --- #### **2. Branded Formulations (Domestic Market)** - **Revenue (FY25):** Over ₹70 crore - **H1 FY26 Revenue:** ₹41 crore - **Revenue Growth (Domestic):** 17% YoY (FY25: Rs. 66.28 crore) - **Focus:** Rebuilding and scaling branded presence in India **Portfolio & Therapeutic Segments:** - **Current Focus Areas:** Anti-cold & cough, anti-infectives, anti-inflammatory, analgesics, antipyretics, orthopaedics, constipation, protein supplements, multivitamins, multimineral supplements. - **Expansion into Specialty Segments:** Paediatrics, dermatology, cardiology, diabetes, gynaecology, critical care, surgery. - **Exclusive Acute Therapies:** Currently offered; strategic shift toward **chronic and specialty care products underway**. **Brand & Distribution Network:** - Manages **10+ active brands**, including legacy brands and new launches: - **Key Brands:** Coriminic, Chymonac, Adtrol, Cusena, Rabiplus, Nurture, Senasof, Nifty-SR, Zeva - **New Launches:** - **Wanbury C-RED / HT-MRY C-RED / RED PAN / PAN RED:** Next-gen **liposomal iron supplement** with enhanced absorption, reduced GI side effects, no calcium chelation. Targets iron-deficiency anemia, gynaecology, and paediatrics. - Positioning as successor to **C Pink** (previously divested). - **Field Force:** 300+ team members - **Channel Network:** 17 C&F agents, 1,800+ distributors - **Doctor Reach:** >30,000 doctors, with emphasis on specialist engagement - **Geographic Reach:** Pan-India presence **Turnaround & Efficiency Initiatives:** - **Project Alliance:** Field force restructuring - **GPS Reporting & Digital Tools:** Improved sales force efficiency - **Marketing Enhancements:** Segmentation, training, SKU refinement - **New SKUs & Value-Added Products:** To mitigate pricing pressure and drive market share --- ### **Financial & Operational Highlights** - **Debt Refinancing (May 2025):** - Refinanced ₹95 crore of high-cost debt (~21% interest) at **12.5% interest**, 5-year tenure, 9-month moratorium - Fundraised ₹175 crore through secured NCDs (Emerging India Credit Opportunities Fund II) - Uses: Debt refinancing, working capital, and capital expenditure - **Balance Sheet:** De-risked with moderate leverage; **Debt/EBITDA ~2x** - **Cost Optimization:** Ongoing initiatives across manufacturing, supply chain, and operations - **Brownfield Expansion:** Potential to add 100 KL reactor capacity across existing sites --- ### **Leadership & Governance** - **Mr. Rashesh Patel:** Over 35 years in pharma; led expansion of Corona Remedies, improving market rank from 107 to 36 (AWACS) - **Mr. Pallavur Sankar Dass Vaidyanathan:** 35+ years; former Dr. Reddy’s Labs executive; expertise in brand building (gastroenterology, cardiovascular, oral care) - **Mr. Manoj Gursahani (Additional Director):** Co-Founder of Vera Healthcare Technologies (AI-based eye disease detection), bringing innovation and strategic governance insights --- ### **Innovation & Differentiation** - **Liposomal Technology:** Flagship launch of **C-RED / RED PAN / PAN RED** iron supplements with superior tolerability and clinical acceptance. - **Strong Regulatory Standing:** USFDA, EU-GMP, and CEP certifications enable access to premium markets. - **Focus on Specialty & Chronic Care:** Positioned for higher-margin, patient-centric therapies beyond commodity generics. ---